CN104955485B - 吡咯并苯并二氮杂卓‑抗her2抗体结合物 - Google Patents
吡咯并苯并二氮杂卓‑抗her2抗体结合物 Download PDFInfo
- Publication number
- CN104955485B CN104955485B CN201380065413.1A CN201380065413A CN104955485B CN 104955485 B CN104955485 B CN 104955485B CN 201380065413 A CN201380065413 A CN 201380065413A CN 104955485 B CN104955485 B CN 104955485B
- Authority
- CN
- China
- Prior art keywords
- group
- antibody
- acid
- groups
- conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CCC*CCOCC*(C)C(CC*(C(CC1C2CC=CCCCCC2)=C)C1=*)=O Chemical compound CCC*CCOCC*(C)C(CC*(C(CC1C2CC=CCCCCC2)=C)C1=*)=O 0.000 description 8
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261712928P | 2012-10-12 | 2012-10-12 | |
| US201261712924P | 2012-10-12 | 2012-10-12 | |
| US61/712,924 | 2012-10-12 | ||
| US61/712,928 | 2012-10-12 | ||
| US201361784249P | 2013-03-14 | 2013-03-14 | |
| US201361784270P | 2013-03-14 | 2013-03-14 | |
| US201361784233P | 2013-03-14 | 2013-03-14 | |
| US61/784,249 | 2013-03-14 | ||
| US61/784,270 | 2013-03-14 | ||
| US61/784,233 | 2013-03-14 | ||
| PCT/EP2013/071343 WO2014057115A1 (en) | 2012-10-12 | 2013-10-11 | Pyrrolobenzodiazepine-anti-her2 antibody conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104955485A CN104955485A (zh) | 2015-09-30 |
| CN104955485B true CN104955485B (zh) | 2018-01-30 |
Family
ID=49552324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380065413.1A Expired - Fee Related CN104955485B (zh) | 2012-10-12 | 2013-10-11 | 吡咯并苯并二氮杂卓‑抗her2抗体结合物 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20150273077A1 (OSRAM) |
| EP (1) | EP2906252B1 (OSRAM) |
| JP (1) | JP2016502504A (OSRAM) |
| KR (1) | KR20150083856A (OSRAM) |
| CN (1) | CN104955485B (OSRAM) |
| AU (1) | AU2013328621B2 (OSRAM) |
| BR (1) | BR112015008177A2 (OSRAM) |
| CA (1) | CA2887896A1 (OSRAM) |
| CY (1) | CY1119287T1 (OSRAM) |
| DK (1) | DK2906252T3 (OSRAM) |
| ES (1) | ES2640449T3 (OSRAM) |
| HR (1) | HRP20171264T1 (OSRAM) |
| HU (1) | HUE034505T2 (OSRAM) |
| LT (1) | LT2906252T (OSRAM) |
| MX (1) | MX2015004423A (OSRAM) |
| PL (1) | PL2906252T3 (OSRAM) |
| PT (1) | PT2906252T (OSRAM) |
| RS (1) | RS56222B1 (OSRAM) |
| SI (1) | SI2906252T1 (OSRAM) |
| SM (1) | SMT201700444T1 (OSRAM) |
| WO (1) | WO2014057115A1 (OSRAM) |
| ZA (1) | ZA201502267B (OSRAM) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| MX368648B (es) | 2010-04-15 | 2019-10-09 | Seattle Genetics Inc | Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas. |
| NZ602932A (en) | 2010-04-15 | 2014-08-29 | Seattle Genetics Inc | Targeted pyrrolobenzodiazapine conjugates |
| MX341524B (es) | 2011-09-20 | 2016-08-24 | Medimmune Ltd | Pirrolobenzodiazepinas como compuestos pbd dimericos asimetricos para inclusion en conjugados dirigidos. |
| AU2012322613B2 (en) | 2011-10-14 | 2016-04-21 | Medimmune Limited | Pyrrolobenzodiazepines and targeted conjugates |
| KR101891859B1 (ko) | 2011-10-14 | 2018-08-24 | 메디뮨 리미티드 | 피롤로벤조디아제핀 |
| CA2850373C (en) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| EP2751110B1 (en) | 2011-10-14 | 2017-04-19 | MedImmune Limited | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative and autoimmune diseases |
| ES2713164T3 (es) | 2012-10-12 | 2019-05-20 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas |
| EP2906249B1 (en) | 2012-10-12 | 2018-06-27 | MedImmune Limited | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
| WO2014057074A1 (en) | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
| JP6307519B2 (ja) | 2012-12-21 | 2018-04-04 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピンおよびその結合体 |
| CN110627797A (zh) | 2012-12-21 | 2019-12-31 | 麦迪穆有限责任公司 | 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 |
| EP2968596B1 (en) | 2013-03-13 | 2019-03-06 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| JP6340019B2 (ja) | 2013-03-13 | 2018-06-06 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン及びそのコンジュゲート |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| EP3054985B1 (en) | 2013-10-11 | 2018-12-26 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| US10188746B2 (en) | 2014-09-10 | 2019-01-29 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| PE20170935A1 (es) | 2014-09-12 | 2017-07-13 | Genentech Inc | Anticuerpos anti-her2 e inmunoconjugados |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| KR20170055521A (ko) * | 2014-09-17 | 2017-05-19 | 제넨테크, 인크. | 항-her2 항체를 포함하는 면역콘주게이트 |
| US10780096B2 (en) | 2014-11-25 | 2020-09-22 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| US9504694B2 (en) | 2015-03-19 | 2016-11-29 | Cellerant Therapeutics, Inc. | Isoquinolidinobenzodiazepines |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| GB201506394D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506389D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
| TWI726942B (zh) | 2015-11-30 | 2021-05-11 | 美商輝瑞股份有限公司 | 位點專一性ｈｅｒ２抗體藥物共軛體 |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| CN106248971B (zh) * | 2016-08-19 | 2017-10-03 | 合肥瀚科迈博生物技术有限公司 | 用于检测人血清中her2含量的elisa试剂盒、使用方法及用途 |
| GB201617466D0 (en) * | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| GB201619490D0 (en) * | 2016-11-17 | 2017-01-04 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| ES2871001T3 (es) * | 2017-02-08 | 2021-10-28 | Adc Therapeutics Sa | Conjugados de pirrolobenzodiazepinas y anticuerpos |
| PL3579883T3 (pl) | 2017-02-08 | 2022-01-24 | Adc Therapeutics Sa | Koniugaty pirolobenzodiazepina-przeciwciało |
| WO2018192944A1 (en) | 2017-04-18 | 2018-10-25 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| JP7402691B2 (ja) | 2017-04-20 | 2023-12-21 | アーデーセー セラピューティクス ソシエテ アノニム | 抗ｃｄ２５抗体薬物複合体による併用療法 |
| CA3057748A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
| JP2020523384A (ja) | 2017-06-14 | 2020-08-06 | アーデーセー セラピューティクス ソシエテ アノニム | 抗ｃｄ２５ ａｄｃを投与するための投与レジメ |
| SG11202000358YA (en) | 2017-08-18 | 2020-02-27 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| AU2018342527B2 (en) | 2017-09-29 | 2024-06-27 | Daiichi Sankyo Company, Limited | Antibody-pyrrolobenzodiazepine derivative conjugate |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| WO2019189453A1 (en) | 2018-03-28 | 2019-10-03 | Mitsubishi Tanabe Pharma Corporation | DRUG CONJUGATES OF cMET MONOCLONAL BINDING AGENTS, AND USES THEREOF |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| US11141490B2 (en) * | 2018-07-13 | 2021-10-12 | Research Foundation Of The City University Of New York | Antibody-drug conjugates based on gold compounds |
| MX2021010477A (es) | 2019-03-15 | 2021-10-01 | Medimmune Ltd | Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer. |
| CN113631190A (zh) * | 2019-03-25 | 2021-11-09 | 第一三共株式会社 | 抗her2抗体－吡咯并苯并二氮杂卓衍生物偶联物 |
| GB201908128D0 (en) * | 2019-06-07 | 2019-07-24 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| MX2022001812A (es) | 2019-08-12 | 2022-03-11 | Regeneron Pharma | Variantes del receptor estimulante de macrofagos 1 (mst1r) y sus usos. |
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
| EP4548932A1 (en) | 2022-06-30 | 2025-05-07 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005085251A1 (en) * | 2004-03-01 | 2005-09-15 | Spirogen Limited | 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines |
| CN101171257A (zh) * | 2005-04-21 | 2008-04-30 | 斯皮罗根有限公司 | 吡咯并苯并二氮杂䓬类化合物 |
| WO2011130613A1 (en) * | 2010-04-15 | 2011-10-20 | Seattle Genetics, Inc. | Targeted pyrrolobenzodiazapine conjugates |
| WO2011130616A1 (en) * | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines used to treat proliferative diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080112961A1 (en) * | 2006-10-09 | 2008-05-15 | Macrogenics, Inc. | Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same |
| GB0819095D0 (en) * | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| US20120183477A1 (en) * | 2009-06-26 | 2012-07-19 | Five Prime Therapeutics, Inc. | Therapeutic Antibody Target Validation and Screening In Vivo |
| BR112012026213B1 (pt) * | 2010-04-15 | 2021-12-28 | Medimmune Limited | Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa |
| WO2011137245A2 (en) * | 2010-04-30 | 2011-11-03 | Esperance Pharmaceuticals, Inc. | Lytic-peptide-her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use |
| PT2707031T (pt) * | 2011-05-08 | 2019-09-05 | Legochem Biosciences Inc | Conjugados de proteína e agente ativo e processo para a sua preparação |
| SG11201401406YA (en) * | 2011-10-14 | 2014-05-29 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2013177481A1 (en) * | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
-
2013
- 2013-10-11 HR HRP20171264TT patent/HRP20171264T1/hr unknown
- 2013-10-11 DK DK13788691.7T patent/DK2906252T3/en active
- 2013-10-11 SI SI201330762T patent/SI2906252T1/sl unknown
- 2013-10-11 MX MX2015004423A patent/MX2015004423A/es unknown
- 2013-10-11 EP EP13788691.7A patent/EP2906252B1/en active Active
- 2013-10-11 KR KR1020157012365A patent/KR20150083856A/ko not_active Withdrawn
- 2013-10-11 LT LTEP13788691.7T patent/LT2906252T/lt unknown
- 2013-10-11 JP JP2015536163A patent/JP2016502504A/ja active Pending
- 2013-10-11 AU AU2013328621A patent/AU2013328621B2/en not_active Ceased
- 2013-10-11 WO PCT/EP2013/071343 patent/WO2014057115A1/en not_active Ceased
- 2013-10-11 SM SM20170444T patent/SMT201700444T1/it unknown
- 2013-10-11 PL PL13788691T patent/PL2906252T3/pl unknown
- 2013-10-11 PT PT137886917T patent/PT2906252T/pt unknown
- 2013-10-11 BR BR112015008177A patent/BR112015008177A2/pt not_active IP Right Cessation
- 2013-10-11 US US14/434,810 patent/US20150273077A1/en not_active Abandoned
- 2013-10-11 RS RS20170839A patent/RS56222B1/sr unknown
- 2013-10-11 HU HUE13788691A patent/HUE034505T2/en unknown
- 2013-10-11 CA CA2887896A patent/CA2887896A1/en not_active Abandoned
- 2013-10-11 CN CN201380065413.1A patent/CN104955485B/zh not_active Expired - Fee Related
- 2013-10-11 ES ES13788691.7T patent/ES2640449T3/es active Active
-
2015
- 2015-04-07 ZA ZA2015/02267A patent/ZA201502267B/en unknown
-
2017
- 2017-09-05 CY CY20171100933T patent/CY1119287T1/el unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005085251A1 (en) * | 2004-03-01 | 2005-09-15 | Spirogen Limited | 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines |
| CN101171257A (zh) * | 2005-04-21 | 2008-04-30 | 斯皮罗根有限公司 | 吡咯并苯并二氮杂䓬类化合物 |
| WO2011130613A1 (en) * | 2010-04-15 | 2011-10-20 | Seattle Genetics, Inc. | Targeted pyrrolobenzodiazapine conjugates |
| WO2011130616A1 (en) * | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines used to treat proliferative diseases |
Non-Patent Citations (1)
| Title |
|---|
| Structure-Activity Relationships of Monomeric C2-Aryl Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) Antitumor Agents;Dyeison Antonow et al;《J. Med. Chem.》;20100310;第 53卷;全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| PL2906252T3 (pl) | 2017-11-30 |
| SMT201700444T1 (it) | 2017-11-15 |
| PT2906252T (pt) | 2017-09-19 |
| KR20150083856A (ko) | 2015-07-20 |
| RS56222B1 (sr) | 2017-11-30 |
| CN104955485A (zh) | 2015-09-30 |
| ES2640449T3 (es) | 2017-11-03 |
| US20150273077A1 (en) | 2015-10-01 |
| SI2906252T1 (sl) | 2017-10-30 |
| AU2013328621A1 (en) | 2015-04-23 |
| MX2015004423A (es) | 2015-10-29 |
| WO2014057115A1 (en) | 2014-04-17 |
| HRP20171264T1 (hr) | 2017-10-20 |
| LT2906252T (lt) | 2017-09-11 |
| EP2906252B1 (en) | 2017-06-14 |
| EP2906252A1 (en) | 2015-08-19 |
| HUE034505T2 (en) | 2018-02-28 |
| BR112015008177A2 (pt) | 2017-09-19 |
| ZA201502267B (en) | 2017-09-27 |
| JP2016502504A (ja) | 2016-01-28 |
| CY1119287T1 (el) | 2018-02-14 |
| AU2013328621B2 (en) | 2016-12-01 |
| CA2887896A1 (en) | 2014-04-17 |
| DK2906252T3 (en) | 2017-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104955485B (zh) | 吡咯并苯并二氮杂卓‑抗her2抗体结合物 | |
| CN105102003B (zh) | 吡咯并苯并二氮杂卓-抗psma抗体结合物 | |
| CN105102004B (zh) | 吡咯并苯并二氮杂卓-抗cd22抗体结合物 | |
| CN105050661B (zh) | 吡咯并苯并二氮杂卓‑抗体结合物 | |
| CN105102068B (zh) | 吡咯并苯并二氮杂卓-抗体结合物 | |
| CN108093640A (zh) | 位点特异性抗体-药物缀合物 | |
| WO2014057114A1 (en) | Pyrrolobenzodiazepine-anti-psma antibody conjugates | |
| WO2014057120A1 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| CN107548306A (zh) | 位点特异性抗体‑药物缀合物 | |
| BR122025001928A2 (pt) | Conjugados de pirrolbenzodiazepina-anticorpo anti-cd22, composição farmacêutica que compreende os mesmos e uso dos conjugados para tratar uma doença proliferativa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180130 Termination date: 20181011 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |